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Abstract 
Voltage gated ion channels are central in defining the fundamental properties of the ventricular 
cardiac action potential (AP), and are also involved in the development of drug-induced 
arrhythmias. Many drugs can inhibit cardiac ion currents, including the Na+ current (INa), L-type 
Ca2+ current (Ica-L), and K+ currents (Ito, Ik1, IKs, and Ikr), and thereby affect AP properties in a 
manner that can trigger or sustain cardiac arrhythmias. Since publication of ICH E14 and S7B 
over a decade ago, there has been a focus on drug effects on QT prolongation clinically, and on 
the rapidly activating delayed rectifier current (IKr), nonclinically, for evaluation of 
proarrhythmic risk. This focus on QT interval prolongation and a single ionic current likely 
impacted negatively some drugs that lack proarrhythmic liability in humans. To rectify this 
issue, the Comprehensive in vitro proarrhythmia assay (CiPA) initiative has been proposed to 
integrate drug effects on multiple cardiac ionic currents with in silico modeling of human 
ventricular action potentials, and in vitro data obtained from human stem cell-derived 
ventricular cardiomyocytes to estimate proarrhythmic risk of new drugs with improved 
accuracy. In this review, we present the physiological functions and the molecular basis of 
major cardiac ion channels that contribute to the ventricle AP, and discuss the CiPA paradigm in 
drug development.  
Key words: Action Potential (AP), Action Potential Duration (APD), Cardiac voltage-gated ion 
channels, INa, Ito, IK1, hERG, IKs, in-vitro study, cardiac action potential, early afterdepolarization 
(EAD), delayed afterdepolarization (DAD), cardiac arrhythmias, QT prolongation, torsade de 
pointes (TdP), patch clamp, comprehensive in-vitro proarrhythmia assay (CiPA) 
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1. Introduction 
In this article we provide a comprehensive overview of major ion currents contributing to 
cellular cardiac electrophysiology. Its scope spans fundamental concepts and more advanced 
considerations. The context is drug-induced proarrhythmia liability. The latest initiative in this 
regard, CiPA, reflects the recognition that arrhythmia liability is determined by the interaction 
between the entirety of the cellular electrophysiology matrix, and not simply one current (IKr). 
1.1 Principles of cardiac cellular electrophysiology 
Voltage-gated ion channels are complex transmembrane spanning proteins that regulate a 
broad spectrum of physiological processes throughout the body (Hille, 1978) including 
excitability of neuronal, skeletal and cardiac muscle cells, as well as modulating contraction and 
relaxation.  In the heart, prominent voltage-gated ion channels include sodium (Na+), potassium 
(K+) and calcium (Ca2+) channels, and their inhibition by drugs can to lead to serious adverse 
effects. KCNH2 gene codes for the Kv11.1 channel, known as the human Ether-à-go-go-Related 
Gene (hERG), which carries the delayed rectifier potassium current, IKr, a key component of 
repolarization during the cardiac action potential (AP). Blockade of IKr delays cardiac 
repolarization, prolonging AP duration (APD) and the QT interval on the ECG, and potentially 
increases the risk for the development of the cardiac arrhythmia, Torsades de Pointes (TdP). 
Because of the historical association of drug induced IKr inhibition with TdP, along with the 
regulatory emphasis on this current, the screening of drugs for effects on additional ventricular 
ionic currents has been largely disregarded in drug safety testing paradigms, despite well 
characterized roles in the cardiomyocyte AP (Pugsley et al., 2015).  
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1.2 Structure of voltage-gated ion channels 
Voltage-gated Na+ and Ca2+ channels consist of a principal pore-forming α-subunit and various 
accessory subunits. The α-subunit of the Na+ channel is approximately 260 kDa, and its function 
is regulated by one or more auxiliary β- subunits (β1-β4) (Figure 1A). Voltage-gated Ca2+ 
channels are formed by a group of subunits, including a pore-forming α-subunit (α1) and at 
least two accessory subunits α2δ and β (Bodi et al., 2005). The voltage-gated Ca2+ channel α-
subunit (Figure 1B) is structurally similar to that of the Na+ channel (Catterall & Swanson, 2015). 
All α-subunits of the Na+ and Ca2+ channels comprise four homologous domains (DI-DIV), each 
of which contains six transmembrane segments (S1-S6). Domains DI-DIV are connected by 
cytoplasmic linkers. Segments S5 and S6 in each domain are connected via a hairpin-like P 
(pore) loop that lines the outer pore of channels (Gellens et al., 1992; Terlau & Stuhmer, 1998). 
In the pore-region of the Na+ channel α submit, an Asp-Glu-Lys-Ala (DEKA) motif determines 
Na+ selectivity. In the Ca2+ channel α subunit four glutamate residues, known as the EEEE motif, 
are responsible for Ca2+ selectivity. The S4 segment in each domain contains positively charged 
amino acid residues and acts as a voltage-gated sensor by moving across the membrane to 
trigger channel activation, in response to membrane depolarization (Yang et al., 1996; Jiang et 
al., 2003). The short cytoplasmic intracellular loop connecting domains III and IV in Voltage-
gated Na+ channel is thought to be the inactivation gate, which bends back into the channel and 
blocks the pore from the inside during sustained depolarization of the membrane (Stuhmer et 
al., 1989; Patton et al., 1992). The inactivation gate is located in the center of a DIII-IV linker 
with a three-amino-acid stretch, consisting of isoleucine, phenylalanine, and methionine (IFM) 
(West et al., 1992). Residues of the S6 segment in each domain often provide the binding site 
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for various drugs (e.g., local anesthetics), and contribute to the formation of the internal 
vestibule in the P-region. The amino (N)- and carboxy (C)- termini of the α-subunits are located 
on the intracellular side of the Na+ and Ca2+ channels, so as to act as the loops that connect the 
repeats of the core motif (Ragsdale et al., 1994). 
K+ channels can be classified into three main groups depending on their pore-forming channel 
structures (Figure 1C). The first group includes the voltage-dependent K currents (Kv) derived 
from six families of channel proteins based upon D. melanogaster nomenclature.  K currents 
included in this group include  the transient outward K+ channel, Ca2+-activated K+ channels and 
KCNQ channels, all of which form tetrameric structures comprised of subunits with six 
transmembrane segments (S1-S6) and cytoplasmic N- and C-termini. The S1-S4 segments move 
in response to voltage changes, functioning as the voltage sensor for the channel. The glycine-
tyrosine-glycine (GYG) motif in the pore region is the critical sequence responsible for K+ 
selectivity (Snyders, 1999). The second group of K+ channels consists of two transmembrane 
segments (S1-S2), conducting three inward K+ currents: the inward-rectifying K+ (Kir) channels, 
ATP-sensitive K+ (KATP) channels and G protein-coupled inwardly-rectifying K
+ (GIRK) channels. 
The S1 and S2 segments are connected by a pore-forming P-loop. Cytoplasmic N- and C-termini 
are similar to the S5, S6 segments in the first group of K+ channels (Loussouarn et al., 2002). The 
third group of K+ channels is the most abundant group with more than 50 members all of which 
a have two-pore (P1 and P2) structure with four transmembrane segments (S1-S4) (Rasmusson 
et al., 1998; Kuang et al., 2015).  
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1.2.1 Voltage-gated Sodium (Na+) channels 
Ten genes encode the distinct Na+ channel α-subunit isoforms (Nav1.1-Nav1.9 and Nax). 
Nav1.1-Nav1.9 isoforms are voltage-dependent channels, whereas Nax (encoded by the SCN7A 
gene), expressed in glial cells within the brain is Na+ concentration-dependent; however, it is 
not homologous to other Na channels and does not exhibit voltage-sensitivity (Noda & Hiyama, 
2015) (Table 1). The Na+ channel isoforms are further characterized pharmacologically by their 
sensitivity to the specific neurotoxin, tetrodotoxin (TTX). The TTX-sensitive (TTX-S) isoforms 
(e.g. Nav1.1-1.4, Nav1.1.6 and Nav1.7) are blocked by nanomolar concentrations of TTX, 
whereas on the other hand, the TTX-resistant (TTX-R) isoforms (e.g. Nav1.5, Nav1.8 and Nav1.9) 
are blocked only by micromolar concentrations of TTX.  Homologous residues, C374 in rNav1.5 
and C373 in hNav1.5, confer resistance to TTX in the rat and human isoforms, respectively 
(Heinemann et al., 1992). 
Cardiac voltage gated Na+ current (INa) properties can be characterized by studying Nav1.5 
channels recombinantly expressed in mammalian cells using the whole cell patch-clamp 
technique. INa typically activates within 200-300μs and inactivates completely within 2-5 ms. INa 
is an inward current characterized by a half maximum activation voltage (V1/2) of approximately 
-50 mV to -55 mV, and  inactivation V1/2 of approximately  -90 mV to -95 mV. Compounds that 
inhibit INa include Class I arrhythmic agents (Milne et al., 1984), various peptide toxins such as 
TTX (Heinemann et al., 1992) and ranolazine (Zygmunt et al., 2001). The “late” component of INa 
has received increased attention over the last few years and is emerging as an important 
contributor to the cardiac APD (Saint, 2009). It is potentially involved in defining rate-
dependent adaption of ventricular repolarization and reverses use-dependence of QT 
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prolonging agents (Guo et al., 2011). Late INa may result from a time-invariant Na
+ “window 
current” (the overlap of INa activation and inactivation voltage-dependent curves), steady-state 
INa or the slowly inactivated portion of INa  (Noble & Noble, 2006; Zaza et al., 2008; Moreno & 
Clancy, 2012).  In the ventricle, the late INa is small, only accounting for around 0.5% of the peak 
amplitude of the fast Na+ current. Its existence has been proposed for decades (Saint, 2008).  
While its physiological role has yet to be fully defined, it has similar biophysical properties to 
the fast Na+ channel including ion channel selectivity and single channel conductance 
properties, but the population that constitute the late channels fail to inactivate after opening 
(Saint, 2008).  In contrast to fast INa, a selective and specific blocker of late INa is still not 
available. However some studies showed that the late current is pharmacologically distinct and 
appears sensitive to block by tetrodotoxin (TTX) and lidocaine as well as ranolazine (Ju et al., 
1992; Saint et al., 1992).   The magnitude of the late Na+ current in the normal heart is small; 
however, its magnitude is increased in many pathologic conditions including ischemia (Zaza et 
al., 2008), heart failure (Pourrier et al., 2014) and congenital long QT syndrome type 3 (LQT3) 
(Wang et al., 1996). This late INa component is thought to maintain the AP plateau (Ju et al., 
1992; Saint et al., 1992; Saint, 2008; Zaza et al., 2008). However, when increased, it can prolong 
the period of ventricular repolarization and drive the Na+/Ca2+ (NCX) exchanger in reverse mode 
leading to an elevated intracellular Ca2+ concentration thereby further increasing the risk of 
generating cardiac arrhythmias (Belardinelli et al., 2006; Noble & Noble, 2006). 
1.2.2 Molecular basis of cardiac (Nav1.5) channels  
Nav1.5 is expressed in the heart, particularly in the intercalated discs (Cohen, 1996; Agullo-
Pascual et al., 2014). However, Nav1.5 channels are also found within the brain (Hartmann et 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
8 
 
al., 1999; Donahue et al., 2000), the gastrointestinal tract (Ou et al., 2002), and neonatal 
skeletal muscle (Kallen et al., 1990). Nav1.5 is encoded by the SCN5A gene, located on 
chromosome 3q21-24. The gene consists of 28 exons spanning approximately 80 kb. It is 2,016 
amino acids in length and has a calculated molecular weight of 227 kDa (Rogart et al., 1989; 
Gellens et al., 1992). There have been two alternatively spliced gene variants identified, termed 
Nav1.5c and Nav1.5d. However, Nav1.5c contains 2,015 amino acids and no glutamine at 
position 1077, thus it is also called Q1077del while Nav1.5d consists of 2,016 amino acids 
containing a glutamine (Q) at position 1077, and therefore it is called Q1077.  mRNA studies 
from the human heart showed the presence of both variants, with levels of Q1077del/Nav1.5d 
being twice those of Q1077/Nav1.5c, in all heart specimens studied (Makielski et al., 2003; Tan 
et al., 2005; Camacho et al., 2006). Thus, in the human heart, alternative splice variants 
(Q1077del and Q1077) may interact with other SCN5A mutations, and cause variable 
biophysical phenotypes that could result in development of various heritable arrhythmias (Tan 
et al., 2005).  
Six groups of β-subunits (β1-β4, β1A, β1B) have been identified in cardiac myocytes with 
different expression levels. β1 is localized to the intercalated discs and T-tubules in the heart, β3 
to the T-tubules, and β2 and β4 to the intercalated discs (Dhar Malhotra et al., 2001; Maier et 
al., 2004). The β1 subunit is non-covalently associated with the α-subunit and regulates Na+ 
current amplitude and the kinetic rate of activation and inactivation of the channel; thus, it has 
a key role in interacting with the α-subunit of the Na+ channel compared with the multiple 
other β-subunits. It has been hypothesized that Nav1.5 channels initiate and propagate cardiac 
APs from one myocyte to the next at intercalated discs, but that β-subunits interact with 
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different Na+ channel isoforms regulating the properties of Na+ channels in discretely different 
ways in the different areas of the heart (Catterall et al., 2003). 
1.2.3 Voltage-gated Calcium (Ca2+) channels  
There are five types of Ca2+ channels, L- (long lasting and large conductance), T- (transient-
opening and small conductance), N- (neuron pre-synapse), P- (Purkinje cells), and R- (resistant 
to peptide toxins) types. The T-type and L-type Ca2+ channels are involved in key roles in the 
heart, contributing to automaticity, cardiac conduction, APs and excitation-contraction (EC) 
coupling. Ca2+ channels (Table 2) influence intracellular Ca2+ homeostasis and its consequences, 
in addition to playing a role in electrogenesis and conduction. In diastole, the intracellular Ca2+ 
concentration is low (~10-8 M). Once Ca2+ enters the cell, it initiates a variety of signaling 
pathways depending on the cell type, including cardiac muscle contraction, release of 
hormones and neurotransmitters, activation of Ca2+-dependent enzymes, and gene 
transcription. Ca2+ channels are classified into three groups: Cav1, Cav2 and Cav3. The Cav1 
group has four members (Cav1.1-Cav1.4), mediating L-type Ca2+ currents and each are 
specifically blocked by the dihydropyridine (DHP) class of calcium channel blocking (CCB) drugs 
(Hess et al., 1986). The Cav2 group includes three members (Cav2.1-Cav2.3) and give rise to the 
P, N and R type currents, respectively. The Cav3 group includes Cav3.1-Cav3.3 and mediates T 
type Ca2+ currents.   
T-type Ca2+ channels are expressed in atria (Bean, 1985) and Purkinje fibers (Hirano et al., 1989) 
as well as in some pacemaker cells (Hagiwara et al., 1988). However, functional T-type Ca2+ 
currents have been difficult to demonstrate in human atrial myocytes. L-type Ca2+ channels are 
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expressed in all regions of the heart. Ca2+ entry into cardiac cells happens mainly through L-type 
Ca2+ channels, leading to Ca2+ release from the sarcoplasmic reticulum and contraction. ICaL also 
plays a significant role in the initiation of  cardiac arrhythmias through early afterdepolarization 
(EAD) related mechanisms (January & Riddle, 1989) and through mediating slow conduction in 
ischaemic myocardium (Curtis, 1990). Because of its importance, Cav1.2 will be further 
discussed in the next section.  
1.2.4 Cardiac voltage gated Ca2+ current (ICa,L)  
During the generation of a cardiac AP, ICa,L is rapidly activated in a voltage- and time-dependent 
manner, and inactivates slowly.  The kinetics of ICa,L activation are nonetheless slower than 
those of INa, taking a few milliseconds to reach peak amplitude. ICaL activates at membrane 
potentials within the voltage range of an AP plateau, in line with a steady-state activation curve 
ranging from -40 mV to +10 mV, with a V1/2  of  around -10 to -5mV (Bers & Perez-Reyes, 1999).  
Steady-state inactivation yields a V1/2 of -40 to -45 mV.  Overlap of activation and inactivation 
voltage-dependent curves allows “window current” fall in the AP plateau voltage range, and 
therefore contributes to the mechanism for EAD generation (January & Riddle, 1989). ICaL 
decreases to almost zero upon repolarization, when the channel responsible for the slow 
delayed rectifier K+ current, IKs, opens and contributes increasingly to membrane repolarization 
(Barhanin et al., 1996). Therefore, the biophysical properties of ICaL contribute, in part, to 
maintaining the plateau phase (Phase 2) of ventricular AP along with the Na+/Ca2+ exchanger 
(NCX), the antiporter membrane protein that removes Ca2+ from cells. Importantly, Cav1.2 is 
the main route of the Ca2+ entry that triggers Ca2+ release from the sarcoplasmic reticulum (SR) 
via its effects on type 2 ryanodine receptors (RyR2).  The intracellular Ca2+ concentration ([Ca]i) 
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is consequently rapidly increased through a process of Ca2+ induced Ca2+ release. The increased 
[Ca]i binds to the myofilaments and initiates cardiac contraction (Bers, 2002). When 
intracellular Ca2+ concentrations reach millimolar concentrations (Lee et al., 1985; Hirano et al., 
1989), a feedback mechanism leads to rapid inactivation of Cav1.2 and results in an 
acceleration of channel recovery from inactivation (Bers & Perez-Reyes, 1999). A prolonged 
plateau provides enough time for ICaL to recover from voltage- and Ca
2+ -dependent 
inactivation, resulting in reactivation and increased inward currents that can further depolarize 
the cardiac membrane potential (January & Riddle, 1989; Ming et al., 1994). In addition, extra 
Ca2+ will be moved into the SR by Ca2+ pumps through sarcoplasmic reticulum Ca2+ ATPase 
(SERCA) pathway or extruded out of cells through the forward mode of the NCX (Lederer et al., 
1990; Bers, 2002). The NCX current (INCX) can generate an inward current at the end of 
repolarization and therefore may contribute to the APD. INCX can be involved in EADs and 
delayed afterdepolarizations (DADs) (Nattel, 2002; Sipido et al., 2007).   
1.2.5 Molecular characteristics of cardiac L-type Ca2+ channels  
There are four subfamilies of voltage-dependent Ca2+ channel pore-forming α1 subunits, Cav1-
Cav4; each subfamily has several family members or splice variants (Lacinova, 2005). Cav1.2 (or 
α1C) is the pore-forming α1 subunit of the cardiac L-type Ca2+ channel, and is encoded by 
CACNA1C. Cavβ2 is the most frequently expressed Cav β subunit in the cardiac L-type Ca2+ 
channel (Perez-Reyes et al., 1992). Cavβ2 is a cytosolic protein that binds to α1C via the DI and 
DII linker, increasing α1C expression and ICaL amplitude and modifying ICaL kinetics (Stotz et al., 
2004). Functional Cav1.2 channel complexes also need another accessory subunit, Cavα2δ 
(Arikkath & Campbell, 2003). Co-expression of Cavα2δ with α1C gives rise to an increased ICaL 
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amplitude and accelerated activation and inactivation (Gurnett et al., 1996). The α1 isoform is 
the ligand-recognition site that determines the effects of drugs on each of the Ca2+ channels in 
the heart.  The L-type Ca2+ channels possess high affinity, stereoselective-binding domains for 
channel blocking drugs, and it is the blockade of these Ca2+ channels in the heart that mediates 
the effects of L-type calcium antagonists on heart rhythm.  
1.2.6 Voltage-gated Potassium (K+) channels 
Cardiac voltage-gated K+ channels play an essential role in AP repolarization and render the 
atrial and ventricular cell equivalent to a ‘potassium battery’ during diastole owing to the K+ 
transmembrane concentration gradient and the fact that the main current active during 
diastole is IK1. The contribution of individual K
+ channels to repolarization can vary depending on 
a number of factors including channel density in different cardiac regions (atrial, ventricular, 
epicardium, endocardium, mid-myocardium, etc.).  This section will focus on four K+ currents, 
namely Ito, IKr, IKs, and IK1. 
1.2.7 Transient outward K+ channel (Ito) 
Ito is composed of two (fast and slow) currents, termed Ito,fast and Ito,slow. Ito,fast displays faster 
gating properties, and contributes to Phase 1 repolarization in APs. In patch clamp studies Ito,fast 
current activates and inactivates rapidly when membrane potentials are depolarized to 
relatively positive potentials above approximately –30 mV. The activation and inactivation 
gating kinetics are time- and voltage- dependent (Greenstein et al., 2000). The time constant of 
activation of Ito,fast is in the order of milliseconds, whereas the inactivation can be described by 
tens to hundreds of milliseconds (Patel & Campbell, 2005). The activation V1/2 is ~+10 mV, while 
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the inactivation V1/2 is around -35 mV in the ventricle (Nabauer et al., 1993; Han et al., 2000). 
Ito,fast is a Ca
2+-independent current.  Ito,slow also shows similarly rapid activation and inactivation 
kinetics, but it recovers slowly from inactivation. Kinetics of recovery from inactivation show 
that the time constants are of ~30-100 ms for Ito,fast and ~100-1000 ms for Ito,slow (Giles & 
Imaizumi, 1988; Patel & Campbell, 2005). Ito,slow is the small Ca
2+-activated component of Ito.  
Ito,fast can be distinguished from Ito,slow by differential sensitivity to the K
+ channel toxins 
Heteropoda toxins (HPTXs) and 4-aminopyridine (4-AP). HPTXs at nanomolar concentrations 
block Ito,fast but not Ito,slow (Sanguinetti et al., 1997). 4-AP blocks Ito,fast in the closed state, but 
also blocks the open state of Ito,slow in a use-dependent manner (Campbell et al., 1993). Three α-
subunit isoforms have been identified in the Ito family. Kv4.2, encoded by gene KCND2, is the 
major α-subunit contributing to Ito,fast in rodents; however Kv4.3, encoded by KCND3, is the 
primary α-subunit for Ito,fast  in larger mammals such as dogs and humans (Nerbonne, 2000). 
Kv1.4 (encoded by KCNA4) displays channel gating kinetics and pharmacological properties 
similar to Ito,slow (London et al., 1998; Patel & Campbell, 2005). In addition to the selective 
blocker 4-AP, Ito,fast is inhibited by many other cardiac drugs including the class Ic antiarrhythmic 
drug flecainide,  the class Ia drug quinidine, the class III drug ambasilide, and the class IV drug 
diltiazem. Quinidine, ambasilide and diltiazem inhibit Ito,fast in the open state and in a frequency-
dependent manner whereas flecainide, propafenone and the class IV drug nifedipine inhibit 
Ito,fast in the closed state in a frequency-independent manner. Blockade of Ito,fast can prolong or 
shorten ventricular repolarization depending on secondary changes in other currents, and by 
affecting plateau duration and voltage.  
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Kv4.2, Kv4.3 and Kv1.4 are pore forming α-subunits underlying cardiac Ito,fast that belong to Kv 
channel Shaker-related subfamilies (Shaker Kv1.x, Shab Kv2.x, Shaw Kv3.x and Shal Kv4.x) 
(Snyders, 1999; Nerbonne, 2000). Ito,fast can also interact with ICaL with the help of the Ca
2+ 
binding protein, KChAP, and thereafter affect the overall Ca2+ entry, APD and EC coupling. In 
particular, KChAP promotes Kv4.3 expression and displays rectifier currents. In addition, DPP6 
(dipeptidyl aminopeptidase-like protein 6) is another subunit of cardiac Kv4.3 which regulates 
Ito,fast expression (Radicke et al., 2005). Ito,fast density is significantly higher in the epicardium and 
mid-myocardium than in endocardium, and thus mediates the notch (i.e., classic spike and 
dome) morphology of APs in epicardial and M cells (Antzelevitch et al., 1999).  
1.2.8 Delayed rectifier K+ currents (IKs and IKr)  
IKr and IKs activate slowly because of a single voltage-dependent gate upon depolarization, and 
because they change the membrane conductance with a delay after a depolarizing voltage step, 
they are named “delayed rectifier” based on the original description of K+ channels in axons by 
Hodgkin et al (1949).  Functional cardiac IKs derive from the co-expression of pore-forming α 
subunits and accessory β subunits. The KCNQ1 gene encodes α subunits, whereas KCNE1 
encodes β subunits. The pore-forming α-subunit underlying IKr is Kv11.1, also known as hERG 
encoded by KCNH2.  IKr is regulated by accessory β subunits encoded by KCNE2 gene. The 
structure of Kv11.1 is similar to the Ito α-subunit structure described in Figure 1C.  
IKs and IKr are important outward currents contributing to Phase 3 repolarization of APs in most 
regions of the heart, but especially within the ventricles. Activation kinetics of IKs are relatively 
slower than those of IKr. The corresponding time constant is in the order of seconds for IKs, but 
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of tens or hundreds of milliseconds for IKr (Cheng & Kodama, 2004). In addition, IKs is activated 
at more positive membrane potentials than IKr, giving a steady-state activation V1/2 value of 
approximately +25 to +30 mV for IKs, and -10 to - 20 mV for IKr. The current- voltage (I-V) 
relationship of IKs is linear due to an extremely slow inactivation processes (Mitcheson & 
Sanguinetti, 1999); whereas IKr displays an inverted bell-shaped I-V relationship because of 
rapid inactivation, with current peaking at potentials ranging between 0 and +10 mV. The fast 
inactivation of IKr at positive membrane potentials accounts for inward rectifying currents 
(Smith et al., 1996), which makes IKr play an additional, albeit small, role in the AP plateau 
(Sanguinetti & Jurkiewicz, 1990). Inactivation is removed as cells repolarize making IKr a key 
player in repolarization. IKr and IKs are expressed in guinea pig, rabbit, dog and human ventricles, 
and are prominent repolarizing currents in these species. In adult rat and mouse ventricles, 
however, their densities are very low or undetectable, and the fast resting heart rate renders 
these currents non-functional even if the channels, or the gene homologues, are present. 
Pharmacological tools can be used to distinguish IKr from IKs. For example, when studying IK in 
guinea pig myocytes, IKr can be selectively blocked by some class III antiarrhythmic agents such 
as E-4031, dofetilide, and D-sotalol (Sanguinetti & Jurkiewicz, 1990; Tamargo et al., 2004), 
leaving a drug-resistant component that is IKs (Sanguinetti & Jurkiewicz, 1990). IKr can also be 
blocked by the class Ia-c antiarrhythmic agents quinidine, mexiletine and flecainide, 
respectively (Tamargo et al., 2004). In addition, non-cardiac-targeting drugs can also inhibit IKr 
at therapeutic concentrations, leading to acquired QT prolongation described in section 4. IKs is 
selectively blocked (compared with actions on other cardiac K currents) by chromanol 293B 
(Busch et al., 1996), the benzodiazepine L-735,821 (Jurkiewicz et al., 1996), the diuretic 
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indapamide (Turgeon et al., 1994) and the chromanol derivative HMR 1556 (Thomas et al., 
2003).  Most of the IKs inhibitors act by blocking the channel in the activated state. The Ca
2+ 
channel blocker bepridil blocks the tail current of IKs more potently with pulses shorter than 600 
ms in an envelope protocol, therefore suggesting that the binding affinity to the channel is 
greater in the closed state (Yumoto et al., 2004), while chromanol 293B and L-735,821 block IKs 
by binding to the pore region and S6 of the α subunits. T312 in the pore region and I337, P339, 
P340, and A344 in the S6 domain are key amino-acid residues contributing to KCNQ1 channel 
block (Seebohm et al., 2003).  
1.2.9 Inward rectifier K+ current (IK1)  
IK1 contributes to Phase 3 repolarization, and plays a major role in setting the resting membrane 
potential in the heart. IK1 conductance is greatest at potentials negative to the K
+ equilibrium 
potential (EK = -90 mV), and is maintained because the channel possesses no inactivation gate 
(and therefore lacks time-dependent inactivation during diastole). IK1 shows strong inward 
rectification, and is voltage-dependent, shifting in conformation to the rested state at positive 
potential. The rectification properties of IK1 result from the fact that outward conductance is 
unidirectionally blocked by intracellular multivalent ions (especially Mg2+) and polyamines 
including putrescine, spermidine and spermine (Nichols et al., 1996; Lopatin & Nichols, 2001). 
IK1 density is greater in the ventricles than in the atria (Melnyk et al., 2002; Schram et al., 2002). 
The current can be inhibited by extracellular Ba2+ and intracellular Cs+, and relatively selectively 
by certain drugs that were developed as potential Class III antiarrhythmics such as RP58866 
(Rees & Curtis, 1993)  Note that unlike the KV channels, Kir channels lack an intrinsic S4 “voltage 
sensing element” and a mechanism for rapid N-type inactivation (i.e., inactivation that occurs 
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by the movement of the cytoplasmic N-terminus to the internal vestibule of the opened 
channel (Hoshi et al., 1991) and therefore do not “sense” and respond to changes in membrane 
potential in the manner of other KV channels, as mentioned above.  The Kir channels are 
nonetheless affected by membrane voltage (Pugsley et al., 2015).   
Cardiac IK1 has three isoforms, which are encoded by three distinct genes: KCNJ2 (Kir2.1), 
KCNJ12 (Kir 2.2) and KCNJ4 (Kir2.3). Kir channel pore-forming α-subunits display a S1-S2 
structure, as described in Figure 1C. Kir2.1 is the most important subunit underlying IK1. 
Mutations in the KCNJ2 gene are linked to LQT7 (Andersen syndrome). KCNJ2 mutant channels 
have a compromised Kir 2.1 function caused by a dominant-negative effect. Affected patients 
may have cardiac electrophysiological changes leading to life-threatening arrhythmias. Kir2.1 
and Kir2.3 are expressed at higher levels in the ventricle than in the atrium (Melnyk et al., 2002; 
Schram et al., 2002).  
2 The Cardiac Action Potential 
Figure 2B demonstrates the different phases in an archetypal ventricular AP. Phase 4 describes 
the resting membrane potential (Em), and has a voltage range of –80 to –90 mV. IK1 is a main 
current active in phase 4 in ventricular cells.  During phase 4, Na+ and Ca2+ channels are in the 
rested state meaning that depolarization (triggered in working heart by electrotonic spread of 
the propagating AP from neighbouring cells) can trigger an AP owing to resultant voltage-
dependent shifts to the activated state of these channels (positive feedback) when 
depolarization reaches the threshold for activation of the Na+ channels (at about –60 mV). In 
the sinoatrial node, the pacemaker current (If) which is a non-selective cation current activates 
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as a result of hyperpolarization, and initiates the propagating AP (Robinson & Siegelbaum, 
2003). Elsewhere, phase 0 is the AP upstroke caused by Na+ channels opening. The maximum 
rate of depolarization during phase 0 (dV/dt max, where dV is the change of membrane potential 
voltage within the depolarisation interval dtmax) determines conduction velocity (Cohen et al., 
1985).  Phase 1 repolarization is characterized by the formation of a notch in the AP and is 
caused by fast time-dependent inactivation of INa and activation of Ito.fast. Phase 2 is the plateau 
that results from the opposing influences of inward (ICa-L) and outward (IKr and IKs) currents. 
Alteration of the amplitude of these currents can increase or decrease the APD and the QT 
interval. Phase 3 is repolarization, and is driven by IKs,  IKr and IK1(Matsuura et al., 1987; 
Sanguinetti & Jurkiewicz, 1990). ICa-L is inactivated during phase 3 (Ono & Iijima, 2010). Finally, 
IK1 becomes activated towards the end of phase 3 (Bodi et al., 2005).  NCX carries an inward 
current that is driven by the membrane potential at the terminal AP repolarization.   
The morphology of cardiac APs has been shown to vary markedly between cardiac regions. For 
example, APs recorded from the sinoatrial (SA) and atrioventricular (AV) nodes display lower 
amplitudes and slow upstroke velocities when compared to ventricular tissue, reflecting the 
more positive Em in diastole (phase 4) and the subsequent reduced contribution of Na
+ current 
and increased contribution of Ca2+ to phase 0 in this tissue (Fig 2C).  In the pacemaker cells of 
nodal tissues phase 4 is characterised by a slow steady spontaneous depolarization, named 
diastolic depolarization, that leads to a ‘threshold’ potential (TP), resulting in the all-or-none 
generation of APs, and pacemaker activity (Bers, 2008). This is due mainly to the presence of 
the non-selective pacemaker or ‘funny’ inward current (If), and a reduced contribution of IK1. 
Atrial APs show a shortened plateau phase and repolarize faster than ventricular cells (Figure 
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2C).  In addition, the ultra-rapid delayed rectifier potassium current (IKur) generated by the 
Kv1.5 channel selectively contributes to phase 3 in human atrial APs (Nattel, 2002; Ruan et al., 
2009).   
2.1 Mechanisms of cardiac arrhythmias being studied 
The surface electrocardiogram (ECG) is the main tool used to diagnose abnormal cardiac activity 
since each of the different segments and intervals represent the activity of specific ion channels 
in discrete regions of the heart.  In humans, common causes of arrhythmias include myocardial 
ischemia, infarction, or reperfusion of a previously ischaemic myocardium.  Most of these 
conditions can be readily reproduced in situ and in ex vivo preparations, such as with 
Langendorff assays.  While the pathology of arrhythmias may not appear to be relevant to the 
safety pharmacologist, our understanding of the underlying ionic mechanisms, based on 
decades of studies in numerous refined non-clinical models, has contributed to the 
development of the CiPA paradigm (see below) in its role of assessing the ‘proarrhythmia 
potential’ for a new drug. For a very comprehensive guide to the study of cardiac arrhythmias in 
humans and animals, see Curtis et al (Curtis et al., 2013) .  
The underlying causes of cardiac arrhythmias are normally inferred, since it is not possible to 
distinguish between re-entry, flow of injury current and abnormal automaticity in an intact 
human, or even an isolated perfused animal heart with any certainty. Indeed, abnormal 
automaticity is an event in a cell and requires single cell AP recording for verification. 
Moreover, unless captured during ECG recordings (i.e., after the patient has begun to receive 
medical assistance), the initiating mechanism underlying arrhythmias can never be determined 
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with certainty. Paradoxically this is most relevant to the most lethal arrhythmias, ventricular 
fibrillation (VF) and sustained TdP which commonly occur unobserved, and in the case of VF the 
first episode a patient experiences is usually lethal if first aid is not administered within 2-3 
minutes of its onset. Unfortunately it is not possible to infer mechanisms of lethal arrhythmias 
by the controlled initiation or observation of spontaneously occurring nonlethal arrhythmias 
because the mechanisms, at least in animal models in which they can be studied, are different 
(Curtis et al., 2013).   
2.1.1 Early and delayed afterdepolarization-induced arrhythmias 
Early afterdepolarizations (EADs) occur during the repolarization phase of the AP (Binah & 
Rosen, 1992).  They are precipitated by bradycardia or long cardiac pauses, allowing for APD 
prolongation and for sufficient time for ICa-L to recover from inactivation, leading to reopening 
of calcium channels within the plateau range and the generation of inward current initiating 
EADs.  In the setting of QT prolongation, a small number of Nav1.5 channels have been shown 
to also remain open within the plateau voltage, carried by the late INa (Saint, 2009; Pugsley et 
al., 2015).  
Delayed afterdepolarization (DAD) is abnormal depolarization interrupting phase 4 of the 
cardiac AP (Figure. 3B) during diastole (Fozzard, 1992).  DADs are dependent upon the duration 
of the diastolic interval but, unlike EADs, the amplitudes of DADs increase during tachycardia.  
DADs may result from an elevated cytosolic Ca2+ concentration in circumstances where the 
cell’s capacity to regulate this is impaired. This may then trigger spontaneous Ca2+ release from 
the SR during repolarization. This so-called setting of Ca2+ overload may be accelerated by 
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digitalis toxicity, β-adrenoceptor stimulation and low extracellular K+. Digoxin toxicity can cause 
diastolic SR Ca2+ release, thereby initiating DAD events (Rosati et al., 2001), and this is likely to 
be exacerbated if there is additional underlying ryanodine receptor dysfunction.  Such 
spontaneous Ca2+ release from the SR extrudes Ca2+ via the NCX and cardiomyocyte 
depolarization, eventually leading to DAD-induced triggered activity (Pogwizd et al., 1999).   
DAD events also induce ventricular tachycardia and fibrillation, but they are precipitated in the 
background of rapid heart rates (Priori et al., 1999).  
2.1.2 Re-entrant mechanisms of arrhythmias 
Although EAD and DAD mechanisms may account for the initiation of some arrhythmias (with 
the caveats outlined at the start of this section), the major (perhaps exclusive) mechanism that 
sustains ventricular arrhythmias is re-entry. Re-entry is failure of an impulse to self-terminate 
owing to the presence of regions of slow conduction that render separate parts of the wave 
front out of synchronization. The slower part of the wave front may then encounter adjacent 
tissue that has recovered excitability and may then propagate in this abnormal direction 
(through the adjacent tissue), re-entering the tissue it excited earlier – the hallmark of re-
entrant arrhythmias (Figure 3C). Abnormalities in cardiac tissue  (e.g, ischemia) can generate a 
tissue substrate for re-entry (Nattel, 2002) by changing conduction velocity or refractory period.  
Injury-induced conduction block facilitates re-entry by creating a region of ‘adjacent’ excitable 
tissue distal to the block, and an island of inexcitable tissue around which a re-entrant circuit 
may flow. This is exacerbated when the block is unidirectional, which is a feature of ischemia-
induced injury in Purkinje fibres. Because the small fibres impinge on larger regions of ventricle 
there is a ‘sink-source mismatch’ and although conduction from Purkinje fibre to ventricle may 
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fail locally, conduction in the opposite direction may be permitted as a consequence of the 
larger current source when an ‘adjacent’ wave front propagates retrogradely from the large 
mass of ventricle into the smaller damaged fibre (Antzelevitch, 2001).    Re-entry can occur in a 
single circuit, or multiple unstable re-entrant circuits simultaneously, producing more irregular 
activity such as multiple monomorphic or polymorphic ventricular tachycardia (VT) or VF (Binah 
& Rosen, 1992).  
3 Heterologous expression systems: in vitro patch clamp electrophysiological studies 
Mammalian cells are used as the principal host for cloned human ion-channel expression 
studies conducted within pharmaceutical drug development. The most common heterologous 
expression systems include human embryonic kidney 293 (HEK 293) cells and Chinese hamster 
ovaries (CHO) cells, both of which are used primarily in the conduct of drug safety 
pharmacology studies.  These systems can be made to over-express ion-channels of interest, 
avoiding contamination by background or endogenous currents. Transient or stable expression 
of exogenous ion channel proteins in these host system is achieved using recombinant DNA 
technology.  Although these expression systems generally yield consistent results, some 
inconsistencies have been highlighted between Xenopus oocytes and HEK 293 cells (Tan et al., 
2003; Farrokhi et al., 2009), in part because of the high level of protein binding that occurs in 
the oocytes related to the presence of the yolk leading to reduced apparent potency for some 
drugs and limiting our ability of determining their TdP liability.    
Studies are usually conducted at room temperature or at physiological temperatures (~37°C).  
While temperature definitely affects channel kinetics, it does not appear to greatly influence 
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potency, with a few exceptions (Kirsch et al., 2004).  Data obtained at either temperature can 
provide important information about drug actions. 
4 Acquired long QT syndrome (aLQTS) 
Certain classes of therapeutic drugs have an associated risk to cause acquired long QT 
syndrome (aLQTs) (Kannankeril et al., 2010). This syndrome represents one of the most critical 
potential side effects for clinical consideration since in certain instances it can lead to the 
potentially lethal arrhythmia, TdP.  (Curtis et al., 2013).  A wide range of drug classes have been 
shown to increase the QT interval, and for many, this is statistically associated with an 
increased risk of TdP including: antiarrhythmics, antihistamines, antibiotics, antimicrobials, 
antipsychotics, oncology agents and others (Table 3). Because of this, aLQTs has been used as a 
risk indicator for TdP (Curtis et al., 2013).  Not all drugs that prolong the QT will cause TdP, not 
all patients with aLQTs will develop TdP, but by definition, all drugs that cause TdP have been 
shown to prolong the QT interval (Curtis et al., 2013). Drugs that prolong QT may be approved 
by FDA, some with a label restriction (e.g., ziprasidone).  While most aLQTs is associated with 
direct inhibition of IKr, some drugs have been shown to affect hERG channel trafficking at the 
cell surface (Marzuillo et al., 2014).  
4.1 Factors affecting TdP liability 
Studies have suggested that pharmacological inhibition of IKr leading to QT prolongation and 
TdP liability is typically mediated through binding to the S6 domain of the α subunit of the 
channel (Mitcheson et al., 2000). Drug exposure is a major factor affecting outcome. Like many 
others, the effects of terfenadine mediated QT prolongation, can be enhanced by the inhibition 
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of cytochrome (CYP) P450 3A4 – resulting in higher plasma concentrations (Jurima-Romet et al., 
1994; Roden, 2004). Similarly, amiodarone (Ohyama et al., 2000) and cisapride (Desta et al., 
2000) were also shown to increase plasma concentrations following CYP3A4 inhibition, 
resulting in a greater prolongation of the QT interval.  Beyond exposure, multiple risk factors 
may exacerbate aLQTs or TdP risk, such as electrolyte imbalance (e.g., hypokalemia, 
hypomagnesemia, and hypocalcaemia), stroke, bradycardia, structural cardiac disease and 
congestive heart failure (Vos et al., 2001).  
4.2 Drug-induced alterations in ion channel trafficking  
Trafficking of ion channels is the process by which newly synthesized proteins are transferred 
from the endoplasmic reticulum (ER) to the cell membrane, and later removed by the early 
endosome and degraded.  Ribosomes produce nascent polypeptides, which are unfolded chains 
of amino acids critical for the ion-channel sequence (Curran & Mohler, 2015).  Subsequently, 
these polypeptides are assembled and properly folded in the ER and Golgi apparatus.  The fully 
synthesized ion-channel proteins are then sorted via the endosome and transported to the cell 
membrane where they are stably expressed. This is the anterograde trafficking pathway.  It is 
balanced by a retrograde trafficking pathway via endosome and lysosome that downregulates 
channel density (Hwang, 2008; Johannes & Popoff, 2008).  
Drugs can alter IKr expression by affecting different steps within the trafficking pathway 
(Cubeddu, 2016).  Many drugs such as tricyclic antidepressants (Dennis et al., 2011), the 
selective serotonin reuptake inhibitor (SSRI) fluoxetine (Hancox & Mitcheson, 2006), the 
macrolide antibiotic erythromycin (Duncan et al., 2006) and the azole antifungal ketoconazole 
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(Takemasa et al., 2008) can affect trafficking. These drugs are thought to reduce channel 
density by inhibiting the transport of the fully mature channel protein from the ER to the 
membrane surface.  Membrane IKr channel density has been shown to be decreased after long-
term exposure to the chemotherapeutic medication arsenic trioxide, which has no direct 
inhibitory effects when perfused directly on to the channels (Drolet et al., 2004).  Instead, 
arsenic trioxide was found to downregulate the chaperon complex formation in the trafficking 
pathway, resulting in the reduced availability of the channel for transport from the ER to the 
cell membrane (Ficker et al., 2004).  The antimicrobial drug pentamidine has also been shown 
to slow the protein maturation process by directly altering the folding processes of IKr channels 
without affecting the chaperon complex (Kuryshev et al., 2005).   Probucol, an anti-
hyperlipidemic drug, increases IKr channel degradation in the trafficking pathway (Guo et al., 
2007). These observations highlight the numerous mechanisms that are involved in channel 
trafficking and the limitations of in vitro drug safety screening that may not have scope for 
assessment of effects on trafficking. Furthermore, many of the drugs that affect trafficking also 
inhibit IKr, providing additive effects on AP prolongation.  
5 The value of assessing the inhibition of multiple cardiac ion channels  
The IKr assay plays a key role in helping to identify, early in the discovery process, compounds 
that have the propensity to prolong the QT interval through IKr inhibition.  However, many 
compounds have inhibitory effects on multiple cardiac ion channels leading to complex 
alterations in the cardiac AP which may or may not translate into prolongation of the QT 
interval and/or a TdP liability.  For example, the Class Ia antiarrhythmic drug, quinidine, is 
known to block multiple ion channels including INa, ICaL and IKr as well as IKs, IK1, IK-ATP and Ito 
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(Salata & Wasserstrom, 1988). However; despite this complex pharmacology it is used to 
restore normal sinus rhythm to patients with symptomatic atrial fibrillation/flutter, and to treat 
patients with life-threatening sustained ventricular tachycardia.  At low therapeutic plasma 
concentrations, it can prolong the QT interval and potentially induce TdP (effects that may be 
related to its IKr blockade); however, at elevated plasma concentrations, multiple ion channel 
block occurs and the potential QT-prolongation effects are reduced (Selzer & Wray, 1964; 
Ometto et al., 1990).  Moreover, the Class IV antiarrhythmic drug, verapamil, has been shown 
to produce equipotent inhibitory effects on ICaL and IKr (Zhang et al., 1999), but does not cause 
QT prolongation or increase risk of TdP because the effects on ICaL mitigate IKr block, leading to 
limited changes in APD and TdP liability (Winters et al., 1985; Fermini & Fossa, 2003).  Even if 
QT prolongation occurs, a drug does not necessarily have a notable TdP liability. For example, 
ranolazine (i.e. inhibition IKr and INalate) may cause QTc prolongation but have not been 
associated with TdP (Martin et al., 2006; Jia et al., 2011).  Thus, proarrhythmic effects emerge 
when the balance between inward and outwards currents is altered significantly. Because of 
the inherent difficulty in understanding and integrating the potential effects of compounds that 
affect multiple ion channels at similar concentrations, the use of logistic regression model may 
likely increase our ability to predict and translate, more efficiently, in vitro ion channel effects 
to in vivo outcomes, as proposed in the CiPA paradigm (Kramer et al., 2013; Colatsky et al., 
2016). 
5.1 Stem cells as a tool for proarrhythmia screening 
There are two types of human stem cells: embryonic (ESC), which originate from fertilized eggs 
with the potential to differentiate into different tissues and organs, and adult pluripotent cells 
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of somatic origin, which have limited gene activation potential, but retain the ability to 
differentiate into only a few types of tissues.  Induced pluripotent stem cells (iPSC) offer the 
potential to assess the risk of drug-induced proarrhythmia using a human derived model. The 
potential advantage is that it is possible to have an assay in which cells express a full range of 
ion channels as expressed in human ventricular myocytes.  This approach is unique as cells can 
be differentiated to express not only normal, but also many variant cardiac disease phenotypes 
(e.g., LQTs (Moretti et al., 2010; Itzhaki et al., 2011; Malan et al., 2011; Egashira et al., 2012; 
Terrenoire et al., 2013), catecholaminergic polymorphic ventricular tachycardia (CPVT) (Yazawa 
et al., 2011), overlap syndrome of cardiac Na+ channelopathy  (Davis et al., 2012) and 
arrhythmogenic right ventricular cardiomyopathy (ARVC) (Ma et al., 2013)).  The potential for 
development of drug-induced arrhythmia may be evaluated by analyzing the parameters for 
each phase of the cardiac AP, as previously described. IPSC cardiac myocytes (iPSC-CM) are 
currently being investigated for use in drug safety ion-channel evaluations.  IPSC-CMs can be 
cultured to obtain a large number of cells and can be used with manual or automated patch-
clamp technology (Himmel, 2013; Mercola et al., 2013).  
Currently, induced pluripotent stem cell-derived cardiomyocytes (IPSC-CMs) are being 
evaluated for their physiological similarity to adult human myocytes.  At the moment, in terms 
of cardiac AP parameters, iPSC-CMs exhibit several distinct differences from adult human CMs.  
IPSC-CMs exhibit a less negative resting membrane potential when compared to adult 
ventricular myocytes (Ma et al., 2011; Davis et al., 2012). In addition, they show major 
differences in ion channel expression levels, especially for IKr and If (Khan et al., 2013).  In 
general, the IPSC-CM phenotype currently used resembles that of a relatively immature CM and 
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exhibits a variable electrophysiological profile when compared to adult CMs (Himmel, 2013).  
Individual IPSC-CMs can exhibit either an atrial or ventricular AP morphology and many 
processes are being developed to enhance ventricular cell differentiation and selection for use 
in studies. As such, AP waveforms recorded from iPSC clusters presently tend to display 
heterogeneous phenotypes.  Thus, it is imperative to improve selection of ventricular CMs for 
study, and further investigation is necessary in order to establish optimal in vitro study 
conditions for use in proarrhythmia screening. 
5.2 CiPA: The next step in proarrhythmia assessment  
The CiPA initiative is a consortium composed of a number of collaborators including, FDA, HESI, 
CSRC, Japan Nation Institute of Health Sciences (NIHS), Health Canada, European Medicines 
Agency (MEA), Pharmaceutical and Medical Devices Agency (PMDA, Japan), Japan iPS Cardiac 
Safety Assessment (JiSCA), academics, in silico modellers, and partners from contract research 
organizations, the pharmaceutical industry and device companies. The new paradigm, has the 
objective to engineer, early in the drug discovery and development process, assays allowing the 
evaluation of the proarrhythmic risk of compounds, instead of concentrating on their ability to 
inhibit the hERG current and to prolong the QT interval (Sager et al., 2014). This new paradigm 
is based on the fundamental mechanistic understanding of the role of ion channels in delayed 
ventricular repolarization, alterations to which lead to repolarization instability and 
arrhythmias.  It is composed of two distinct nonclinical series of tests: 1) the in vitro study of 
drug effects on multiple ion channels (not just hERG), and incorporation of these effects in an in 
silico model of a human ventricular action potential (AP) in an effort to reconstruct the effects 
on ventricular repolarization and identify potential mechanism-based metrics that can assess 
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proarrhythmia risk, and 2) confirmation of in silico results using human ventricular myocytes, 
likely derived from human induced pluripotent stem cell (iPSC)  cardiomyocytes (Fermini et al., 
2016).  
The in silico models will be built prospectively, using known torsadogenic drugs of varying risks.  
The iPSC-CM electrophysiology studies will be useful in confirming predictions based on the in 
silico model, as will phase I ECG studies in clinical trials should that data be available at the time 
of conduct of the CiPA assay.  Additionally, ion channel inhibition protocols will be 
standardized, and will likely include multiple pharmacological endpoints.  The in silico model 
will recapitulate the cardiac AP based on drug effects on these multiple ion channels and be 
aimed at determining potential (yet to be determined) proarrhythmia markers rather than just 
effects on APD alone.  Drugs will be rank ordered for proarrhythmia risk. In vivo ECG analysis in 
both animals (SP CV studies) and humans (Phase I clinical trials) will play important roles in 
evaluating risk and confirming CiPA outcomes.   
6 Conclusion  
Proarrhythmia risk assessment for drug-induced TdP is constantly evolving.  Over the years, 
cardiac ion channel testing emerged as an important tool for this.  The proarrhythmia screening 
methodologies have migrated from an ‘hERG centric’ approach to a more integrated strategy 
including a broader spectrum of in vitro cardiac ion channel data, in silico modelling, in vivo 
studies and clinical trial data to protect later stage clinical trial participants and ultimately 
patients.  The next decade of research in proarrhythmia risk assessments will require honing of 
the integrated risk assessment, now named CiPA, and validation of its component parts and the 
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way it is deployed to best effect. This may help avoid throwing ‘the baby out with the bath 
water’. The evolution of the CiPA methodology is certain to give rise to publications, propelled 
by increasing knowledge of drug effects on cardiac electrophysiology.  
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Table 1. Some properties of voltage-gated Na
+
 channels 
Channel Gene 
TTX 
sensitivity* 
Tissue location 
Nav1.1 SCN1A Sensitive CNS, PNS, heart 
Nav1.2 SCN2A Sensitive CNS, hear 
Nav1.3 SCN3A Sensitive CNS, heart 
Nav1.4 SCN4A Sensitive Skeletal muscle 
Nav1.5 SCN5A Resistant Heart, CNS 
Nav1.6 SCN8A Sensitive 
CNS, PNS, heart, glia, nodes of 
Ranvier 
Nav1.7 SCN9A Sensitive PNS, Schwann cells 
Nav1.8 SCN10A Resistant PNS 
Nav1.9 SCN11A Resistant PNS 
Nax SCN6A/SCN7A Resistant CNS, PNS, heart  
CNS, Central nervous system; PNS, peripheral nervous system; TTX, Tetrodotoxin; 
 The isoform of the Na+ channel is ‘sensitive’ if the channel is blocked at nM concentrations 
and resistant if blocked at µM concentrations  
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Table2.  Some properties of voltage-gated Ca
2+
 channels  
Channel  αSubunit/ 
 
Gene Accessory 
subunits 
DPH 
sensitivity* 
Tissue location 
L Cav1.1 (α1S) CACNA1S α2δ, β, γ Sensitive Skeletal muscle, 
Cav1.2  (α1C) CACNA1C α2, β, γ Sensitive Hear (ventricle), CNS, 
smooth muscle, bone, 
adrenal gland 
Cav1.3  (α1D) CACNA1D α2, β, δ Sensitive CNS, pancreas, kidney, 
cochlea 
Cav1.4  (α1F) CACNA1F unknown Sensitive Retina 
P/Q Cav2.1 ( (α1A) CACNA1A α2δ, β Resistant CNS (cerebellum)  
N Cav2.2  (α1B) CACNA1B α2δ/β1, β2, β3, Resistant CNS (brain) and peripheral 
nerve system 
R Cav2.3  (α1E) CACNA1E α2δ, β Resistant CNS (cerebellum, neurons) 
T Cav.3.1  (α1G) CACNA1G unknown Resistant Heart (SA node), CNS 
(neurons), bone  
Cav.3.2  (α1H) CACNA1H unknown Resistant Heart (SA node), CNS 
(neurons), bone  
Cav.3.3  (α1I) CACNA1I unknown Resistant CNS (brain) 
CNS, Central nervous system; DPH, dihydropyridine 
 The isoform of the Ca2+ channel is ‘sensitive’ if the channel is blocked at nM concentrations 
and resistant if blocked at M concentrations  
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Table 3. Drugs with an increased propensity for the development of QT prolongation and 
precipitation of Torsades de Pointes (TdP) arrhythmias  
Compound category Compound Compound category Compound 
Antiarrhythmic drugs 
(Class IA, Class III and 
Class IV) 
Ajmaline  Anticancer drugs Prenylamine 
Quinidine  Arsenic trioxide 
Procainamide  Antihistamines Astemizole  
Disopyramide  Diphenhydramine  
Propafenone  Loratadine  
Almokalant  Terfenadine  
Azimilide  Psychiatric Drugs Amitriptyline  
Dofetilide  Chlorpromazine  
Ibutilide  Chloral hydrate  
Sotalol  Citalopram  
Amiodarone  Doxepin  
Tedisamil  Droperidol  
Verapamil Haloperidol  
Dronedarone   Imipramine  
Antimicrobial drugs Amantadine  Lithium  
Azithromycin  Maprotiline  
Clarithromycin  Pimozide  
Erythromycin  Sertindole  
Fluconazole  Thioridazine  
Grepafloxacin  Zimelidine  
Itraconazole  Ziprasidone 
Ketoconazole  Vasodilators Bepridil  
Pentamidine  Lidoflazine  
Sparfloxacin  Vandetanib 
Trimethoprimsulfamethoxazole Others Cisapride  
Antimalarial drugs Chloroquine  Domperidone  
Halofantrine  Cesium 
Source: www.torsades.org; Woosley, RL and Romero, KA,  www.Crediblemeds.org,  QTdrugs List, 
[March 8, 2016], AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ  85755] 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
64 
 
 
 
Figure 1: A schematic view of the structure of voltage-gated Na
+
, Ca
2+
 and K
+ 
channels. A) The Na
+
 
channel α-subunit is inserted into the lipid bilayer of the cellular membrane and constitutes the channel 
pore, through which Na
+ 
ions pass. The subunit consists of four domains (DI-IV). Each domain contains 
six transmembrane segments. The pore is composed of segments S5-S6, while S4 acts as the voltage 
sensor. β-subunits have a single transmembrane segment, a long extracellular N-terminus, and a short 
intracellular C-terminus. B) The Ca
2+
-channel α1 subunit demonstrates a similar structural basis to the 
Nav channels. The α2δ and β subunits enhance expression and modulate the voltage dependence and 
gating kinetics of the α1 subunit. C) The K+-channel α subunit. The top panel shows voltage-dependent 
K
+
 -channel (Kv) α subunits that contains six transmembrane segments (S1-S6) with one K+-conducting 
pore. The middle panel shows inward-rectifying K
+
-channel (Kir) α subunits that contains two 
transmembrane segments with one pore region. The bottom panel shows the K2P model that contains four 
transmembrane segments with two pores.  
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
65 
 
 
Figure 2. The cardiac electrical conduction system and genesis of the cardiac action potential in 
fast-response and slow-response tissues. A) The basic cardiac structure and components involved in 
conduction of electrical impulses from the sinus node through the His-Purkinje system. B) A schematic of 
action potentials in fast-response and slow-response tissues. The bottom left panel demonstrates a typical 
morphology of a cardiac action potential in fast-response tissues (i.e., atrial and ventricular myocardium 
and Purkinje fibers). Each action potential comprises phase 0 through phase 4. Some channels may 
conduct in an inward or outward direction, depending on the membrane voltage at any given time point of 
the electrical cycle. Upright/downright arrows represent depolarizing and repolarizing currents, 
respectively. The bottom right panel demonstrates a cardiac action potential in slow-response tissue (i.e., 
the SA node and AV node). 
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Figure 3. Mechanisms underlying the development of cardiac arrhythmias. A) An early 
afterdepolarization (EAD)-induced action potential. B) Delayed afterdepolarizations (DAD)-triggered 
action potentials. C) Substrate of re-entry for ventricular arrhythmia development. The bottom left panel 
represents the normal conduction in a bifurcated pathway. The bottom middle panel indicates that 
electrical conduction is blocked in an area of refractory tissue (i.e., unidirectional block). The bottom 
right panel shows that if conduction velocity is slower than the tissue refractory period, then reentry can 
occur. See text for details. 
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